Evidence map›Paper›PMID 26497367›Full record

ArticleOncotarget2015

miR-124 and miR-506 inhibit colorectal cancer progression by targeting DNMT3B and DNMT1.

Zhiheng Chen, Shaojun Liu, Li Tian, Minghao Wu, Feiyan Ai, Wuliang Tang, Lian Zhao, Juan Ding, Liyang Zhang, Anliu Tang

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers.

0numbers the graph read from it
0cells of the map it votes in
50citing papers in PubMed
3.5field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

50 citing papers in PubMed, 86 citations in OpenAlex.

  1. Article
  2. Review
  3. Fumonisin BEpigenetics · 2025
    Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Zhiheng ChenDepartment of Pediatrics, The Third Xiangya Hospital, Central South University, Changsha, Hunan, China.
Shaojun LiuDepartment of Gastroenterology, The Third Xiangya Hospital, Central South University, Changsha, Hunan, China.
Li TianDepartment of Gastroenterology, The Third Xiangya Hospital, Central South University, Changsha, Hunan, China.
Minghao WuDepartment of Gastroenterology, The Hunan Provincial People's Hospital, Changsha, Hunan, China.
Feiyan AiDepartment of Gastroenterology, The Third Xiangya Hospital, Central South University, Changsha, Hunan, China.
Wuliang TangDepartment of Gastroenterology, The Third Xiangya Hospital, Central South University, Changsha, Hunan, China.
Lian ZhaoDepartment of Gastroenterology, The Third Xiangya Hospital, Central South University, Changsha, Hunan, China.
Juan DingDepartment of Oncology, The Third Xiangya Hospital, Central South University, Changsha, Hunan, China.
Liyang ZhangDepartment of Neurosurgery, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Anliu TangDepartment of Gastroenterology, The Third Xiangya Hospital, Central South University, Changsha, Hunan, China.
Central South University · CNThird Xiangya Hospital · CNHunan Provincial People's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

miR-124 and miR-506 are reportedly down-regulated and associated with tumor progression in many cancers, but little is known about their intrinsic regulatory mechanisms in colorectal cancer (CRC). In this study, we found that the miR-124 and miR-506 levels were significantly lower in human CRC tissues than in controls, as indicated by qRT-PCR and in situ hybridization histochemistry. We also found that the overexpression of miR-124 or miR-506 inhibited tumor cell progression and increased sensitivity to chemotherapy in vitro. Increased miR-124 or miR-506 expression also inhibited tumor cell proliferation and invasion in vivo. Luciferase reporter assays and western blotting were used to determine the association between miR-124, miR-506 and their target genes, DNMTs. We further identified that miR-124 and miR-506 directly targeted DNMT3B and indirectly targeted DNMT1. The overexpression of miR-124 and miR-506 reduced global DNA methylation and restored the expression of E-cadherin, MGMT and P16. In conclusion, our data showed that miR-124 and miR-506 inhibit progression and increase sensitivity to chemotherapy by targeting DNMT3B and DNMT1 in CRC. These findings may provide novel avenues for the development of targeted therapies.

Indexed as

AnimalsAntigens, CDAntineoplastic AgentsCadherinsCell MovementCell ProliferationColorectal NeoplasmsCyclin-Dependent Kinase Inhibitor p16Disease ProgressionDNA (Cytosine-5-)-Methyltransferase 1DNA (Cytosine-5-)-MethyltransferasesDNA MethylationDNA Methyltransferase 3BDNA Modification MethylasesDNA Repair EnzymesDose-Response Relationship, DrugAntigens, CDAntineoplastic AgentsCadherinsCDH1 protein, humanCyclin-Dependent Kinase Inhibitor p16DNA (Cytosine-5-)-Methyltransferase 1DNA (Cytosine-5-)-MethyltransferasesDNA Methyltransferase 3BDNA Modification MethylasesDNA Repair EnzymesDNMT1 protein, humanDnmt1 protein, mouseMGMT protein, humanMicroRNAsMIRN124 microRNA, humanMIRN506 microRNA, humanTumor Suppressor Proteinscolorectal cancerDNMT1DNMT3BmiR-124miR-506

Identifiers

PMID26497367
PMCPMC4741989
OpenAlexW2252689760

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.